VIEW
IN BROWSER
EDITOR'S
NOTE: Big4Bio
newsletters will not be published Nov 23rd-27th;
they will resume distribution on Monday, Nov 30th.
|
|
|
November 17, 2026 |
| Regional
intelligence on Drugs, Diagnostics,
Devices & Digital Health |
|
|
|
* may need subscription to view |
|
BIG4BIO
CEO WEEKLY Q&A:
Oren Gilad, Ph.D., President & CEO,
Aprea Therapeutics |
| In
this Q&A, Gilad discusses what
differentiates APR-1051 from earlier WEE1
inhibitors, the biomarker strategy behind
Aprea's approach to precision oncology,
milestones the company is working toward,
and realities of leading a clinical-stage
biotech through scientific and financial
uncertainty. More |
|
|
- Biocon: Gets U.S. FDA Approval for Pebrilzo
(pertuzumab-qcay) Injection, a Biosimilar to
Perjeta, Expanding Its Oncology Portfolio More
- Cognition Therapeutics: CTAD Poster
Highlighting Screening Efficiencies With
p-Tau217 in the Ongoing Phase 2 START Study
More
- Cognito: Pivotal Phase 3 Results for
Spectris AD, a Non-Invasive, At-Home Approach
for Alzheimer’s Treatment, Backed by ADDF
Investment More
- Corxel US: Presents Full Phase 2 Results for
CX11 in Adults With Overweight and Obesity at
ObesityWeek 2026 More
- Feinstein Institutes: Dr. Kevin J. Tracey
Receives Cold Spring Harbor Laboratory Double
Helix Medal More
- Helus Pharma: Positive Topline
Results From Phase 3 APPROACH Study
Evaluating HLP003 as Adjunctive Treatment in
Major Depressive Disorder More
More
More*
More*
- Kos Biotechnology Partners and FORTH:
Strategic Partnership to Advance Biotechnology
Innovation in Greece More
- Novo: Presents Preclinical and Human Data
Suggesting a Role for Amylin and Calcitonin
Receptor Activation in Preserving Bone During
Weight Loss at ObesityWeek More
- Novo: Wegovy Resulted in a BMI Reduction of
10% or More in Almost 80% of Children With
Obesity Aged 6 to Under 12, Compared to 0%
With Placebo in Step Young Trial, Published in
the New England Journal of Medicine More
- Nuvation Bio: Presented Additional Long-Term
Follow-Up Data From Phase 2 Study of
Safusidenib in IDH1-Mutant Glioma at the 2026
Society for Neuro-Oncology Annual Meeting More
- Precision Neuroscience and Team Gleason:
Partner to Give the ALS Community a Voice in
Brain–Computer Interface Development More
- Regeneron: Libtayo (cemiplimab) Approved in
the European Union (EU) for Extended Dosing
and Faster Infusion Times Across Skin, Lung
and Cervical Cancer Indications
More
- SELLAS Life Sciences: Positive Pivotal Phase
3 REGAL Trial Data Showing Immunotherapeutic
Cancer Vaccine, Galinpepimut-S (GPS),
Demonstrated a Statistically Significant and
Clinically Meaningful Improvement in Overall
Survival in Patients with Acute Myeloid
Leukemia More
More
- Teva: U.S. FDA Approves IGALMI as
First At-Home Acute Treatment for Agitation
Associated With Schizophrenia,
Schizoaffective Disorder, or Bipolar I or II
Disorder in Adults
More
|
|
- ADM Tronics: Second Quarter of Fiscal Year
2027 Results More
- Dana Foundation: 2026 Neuroscience &
Society Champion Award Recipients More
- Interpace Biosciences: Third Quarter 2026
Financial and Business Results More
- More on J&J Buying Eye Disease
Biotech Ollin Biosciences for Up to $3.3B More*
More*
More
More
- Palatin: Fiscal First Quarter 2027 Financial
Results and Business Update More
- SCIENTURE: Q3 2026 Results With
Approximately 265% Sequential Revenue Growth
Driven by the Commercial Launch of REZENOPY More
- Vaso Corporation: Financial Results for
Third Quarter of 2026
More
|
|
- Big4Bio CEO Weekly Q&A: Oren
Gilad, Ph.D., President & CEO, Aprea
Therapeutics More
- Biotech & Pharma Updates | November 16,
2026 More
- Strategic Intent: Praxis CEO on
“Unlearning,” AI and Launching Two
Neuroscience Drugs at Once Podcast
- Subscribe to LifeSci Startup for
Updates on US Startups More
|
|
 |
|
| Slone
Partners Places Farhad Ghavami as
Chief Executive Officer at
SeqCenter |
|
Learn More
→ |
|
|
- ICYMI: Milestone Cuts 20% of Staff With CMO,
CFO Exiting Leadership Roles
More*
More
- ICYMI: More on Cellectis Shedding 70% of
Workforce as Part of In Vivo Pivot More
More
- OPPORTUNITY: Director of Compliance, Remote
More
- OPPORTUNITY: Head of Market
Development & Strategy, California More
- OPPORTUNITY: Senior Vice President,
Regulatory Affairs & Quality Assurance,
Boston More
- Slone Partners: Doing More With Less
- Building the Right Nonprofit Leadership
Team in a Resource-Constrained Environment More
- Slone Partners: Leading Through AI - The New
Playbook for Healthtech Executives More
- Tris Pharma: Named a BioSpace 2027 Best
Places to Work Winner
More
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: NYC Life Science Company
Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
|
|
|
|
|
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:NYC,
all rights reserved 2026
© 2026
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|